Iso-osmolar agent showshigher renal failure rate

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 1
Volume 31
Issue 1

Radiologists hoped the introduction of isoosmolarcontrast media would eliminatesevere adverse reactions to x-ray contrast.Alas, it was not to be.

Radiologists hoped the introduction of isoosmolar contrast media would eliminate severe adverse reactions to x-ray contrast. Alas, it was not to be. A large retrospective Swedish study identified a significantly higher rate of renal failure among patients administered iso-osmolar iodixanol (Visipaque) compared with patients who received low-osmolar ioxaglate (Hexabrix).

Dr. Per Liss and colleagues at the University of Uppsala presented their evaluation of 23,224 patients at the 2008 RSNA meeting. They found that 1.7% of patients who received iodixanol developed primary or secondary renal failure within 12 months of administration. The 12-month renal failure rate for patients who received ioxaglate was 0.8%.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Diagnostic Imaging’s Top Five Breast Imaging Content: Summer 2025
Reducing Mammography Workload by Nearly 40 Percent? What a New Hybrid AI Study Reveals
 What New Research Reveals About Portable Low-Field MRI and Patients with Suspected Alzheimer’s Disease
© 2025 MJH Life Sciences

All rights reserved.